Archive | Clinical Trials

Personalized Cancer Vaccines Look Promising in Two New Studies

A vaccine that teaches the body to selectively destroy tumors has eluded cancer researchers for decades. Despite many clinical trials, such vaccines have shown little to no success.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Encorafenib/Binimetinib a Potential New Treatment Option for BRAF-Mutant Melanoma

BRAF inhibitor encorafenib (LGX818) combined with the MEK inhibitor binimetinib (MEK162) reduced the risk of progression or death by 46% compared with vemurafenib (Zelboraf) for patients with BRAF-mutant unresectable melanoma, according to findings from cohort 1 of the phase III COLUMBUS trial.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma survival extension with adjuvant ipilimumab comes at toxicity cost

medwireNews: Updated phase III trial results show that ipilimumab treatment improves overall survival (OS) and distant metastasis-free survival in stage III melanoma patients who have undergone complete resection, but with increased toxicity relative to placebo.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma

Neoadjuvant therapy with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is plausible and effective but can induce a high level of adverse events (AEs) calling for further research into better tolerated dosing schemes, according to findings from the OpACIN trial presented at the 2016 Society for Melanoma Research Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories